RxDoctor Payments DataLook up a doctor →

Deryll Ambrocio, MD

Rheumatology · Honolulu, HINPI 1730301219

Payments from drug & device makers

$21,072in general payments, 2019–2025

Across 597 payments — averaging $35.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$8K
  • Amgen$7K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Novartis$556
  • Insmed, Inc.$544
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$8,75042%
  • Food & beverage$12,32258%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,072 in reported general payments places this provider in the 85th percentile of 21 rheumatology providers in Hawaii.

See all rheumatology providers in Hawaii

Medicare billing

Part B allowed, 2024
$1,133,006
Medicare patients
335
Services billed
58,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab61$413,167
Enbrel SureclickEtanercept26$208,666
Orencia ClickjectAbatacept18$155,548
RinvoqUpadacitinib20$129,267
Xeljanz XrTofacitinib Citrate19$127,219
OtezlaApremilast22$114,514
EnbrelEtanercept13$93,680
ProliaDenosumab26$45,884
Actemra ActpenTocilizumab13$35,451
Mycophenolic AcidMycophenolate Sodium30$16,240
Mycophenolate Mofetil49$9,682
MethotrexateMethotrexate Sodium242$8,802
Leflunomide54$4,935
Hydroxychloroquine Sulfate44$4,245
Diclofenac Sodium46$3,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel, Prolia$7,254$254,07961 claims
AbbVieRinvoq$1,778$129,26720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 rheumatology providers in Hawaii.

Other rheumatology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →